Literature DB >> 2060534

Clindamycin/primaquine for treatment of Pneumocystis carinii pneumonia in AIDS.

E Toma1.   

Abstract

In an open clinical trial, 109 episodes of Pneumocystis carinii pneumonia (70 proven and 39 highly probable) were treated with clindamycin/primaquine. These episodes were in 35 patients who failed on standard therapy and 15 who did not tolerate standard therapy; 59 patients received this regimen as their initial treatment. The clinical outcome was excellent with only 8 cases of failures encountered (6 patients also failed on standard therapy). The onset of clinical response was obvious in less than 72 hours in 81% of patients; the relapse rate was very low. The regimen was well tolerated and compares advantageously with conventional therapy for Pneumocystis carinii pneumonia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060534     DOI: 10.1007/bf01964467

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

Review 1.  Pulmonary infectious complications of human immunodeficiency virus infection. Part II.

Authors:  J F Murray; J Mills
Journal:  Am Rev Respir Dis       Date:  1990-06

2.  Clindamycin/primaquine for Pneumocystis carinii pneumonia.

Authors:  B Ruf; H D Pohle
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

3.  Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.

Authors:  I Medina; J Mills; G Leoung; P C Hopewell; B Lee; G Modin; N Benowitz; C B Wofsy
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

Review 4.  Pneumocystis carinii pneumonia: therapy and prophylaxis.

Authors:  J A Kovacs; H Masur
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

5.  Clindamycin with primaquine for Pneumocystis carinii pneumonia.

Authors:  E Toma; S Fournier; M Poisson; R Morisset; D Phaneuf; C Vega
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

6.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

  6 in total
  5 in total

1.  Antibiotic-associated diarrhea in HIV-infected patients receiving clindamycin.

Authors:  H Slevogt; B Ruf
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

Review 2.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

4.  8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; M Nasr; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

5.  Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.

Authors:  N P Dhammika Nanayakkara; Arba L Ager; Marilyn S Bartlett; Vanessa Yardley; Simon L Croft; Ikhlas A Khan; James D McChesney; Larry A Walker
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.